Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Júlia S M DiasInstituto de Química, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas 37130-000, MG, Brazil.
Guilherme A Ferreira-SilvaDepartamento de Ciências Biomédicas, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas 37130-000, MG, Brazil.
Rommel B VianaDepartamento de Química, Universidade Estadual do Ceará (UECE), Limoeiro do Norte 62930-000, CE, Brazil.ORCID 0000-0002-4336-677X
João H de Araujo NetoInstituto de Química, Universidade de São Paulo (USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-1127-6083
Javier EllenaInstituto de Física de São Carlos, Universidade de São Paulo (USP), São Carlos 13566-590, SP, Brazil.ORCID 0000-0002-0676-3098
Rodrigo S CorrêaDepartamento de Química, Universidade Federal de Ouro Preto (UFOP), Ouro Preto 35400-000, MG, Brazil.ORCID 0000-0003-2783-0816
Marília I F BarbosaInstituto de Química, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas 37130-000, MG, Brazil.
Marisa IontaDepartamento de Ciências Biomédicas, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas 37130-000, MG, Brazil.ORCID 0000-0001-8796-1426
Antônio C DoriguettoInstituto de Química, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas 37130-000, MG, Brazil.ORCID 0000-0002-2726-1265
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior PNPD and MS grant - Finance Code 001Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00544-23Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01305-24Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01835-18Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02036-21Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-05218-23Fundação de Amparo à Pesquisa do Estado de Minas Gerais BPD-00644-22Fundação de Amparo à Pesquisa do Estado de Minas Gerais RED-00116-23Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/15850-0National Council for Scientific and Technological Development 312433/2023-9National Council for Scientific and Technological Development 312505/2021-3National Council for Scientific and Technological Development 408475/2023-4
6 · The paper itself
Abstract
backgroundMelanoma is the most aggressive and lethal skin cancer that affects thousands of people worldwide. Ruthenium complexes have shown promising results as cancer chemotherapeutics, offering several advantages over platinum drugs, such as potent efficacy, low toxicity, and less drug resistance. Additionally, anthraquinone derivatives have broad therapeutic applications, including melanoma.
objectivesThus, two new ruthenium complexes with 1-hydroxy-9,10-anthraquinone were obtained:
methodsThe complexes were characterized by infrared (IR), UV-vis,
resultsCompound (
conclusionsThe cytotoxicity profiles of the compounds were evaluated in human melanoma cell lines (SK-MEL-147, CHL-1, and WM1366), revealing greater cytotoxic activity for (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ruthenium(II) Complex with 1-Hydroxy-9,10-Anthraquinone Inhibits Cell Cycle Progression at G0/G1 and Induces Apoptosis in Melanoma Cells. · full record | OpenQuestion